End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.742 USD | -7.52% | -16.63% | -97.27% |
May. 21 | Earnings Flash (SBFM) SUNSHINE BIOPHARMA Posts Q1 Revenue $7.5M | MT |
May. 20 | Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 44.94M | Sales 2025 * | 100M | Capitalization | 738K |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | 11M | EV / Sales 2024 * | 0.02 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 0.01 x |
P/E ratio 2024 * |
-74.2
x | P/E ratio 2025 * |
1.24
x | Employees | 44 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.5% |
1 day | -7.52% | ||
1 week | -16.63% | ||
Current month | -15.20% | ||
1 month | -38.68% | ||
3 months | -85.87% | ||
6 months | -97.03% | ||
Current year | -97.27% |
Managers | Title | Age | Since |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Marc Beaudoin
COO | Chief Operating Officer | - | Jan. 24 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 22-01-31 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 09-10-14 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 09-10-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 0.742 | -7.52% | 2,177,643 |
24-05-22 | 0.8023 | -0.41% | 2,584,381 |
24-05-21 | 0.8056 | -17.80% | 5,870,688 |
24-05-20 | 0.98 | +5.38% | 4,038,734 |
24-05-17 | 0.93 | +4.49% | 4,037,246 |
End-of-day quote Nasdaq, May 22, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-97.27% | 738K | |
+38.69% | 728B | |
+33.66% | 603B | |
-4.49% | 360B | |
+20.24% | 332B | |
+2.12% | 279B | |
+15.77% | 244B | |
+7.68% | 207B | |
-5.44% | 205B | |
-0.35% | 163B |
- Stock Market
- Equities
- SBFM Stock